A Pick-Me-Up for German Pharma

The Bayer-Schering combo will be big enough to take on the giants of the global drug industry. The new entity is sure to have a richer pipeline

It promised to be a lengthy takeover tussle between two of Germany's leading drugmakers. But two weeks after launching its $17.4 billion hostile bid for Schering (SHR), drug and chemical giant Merck (MRK) threw in the towel.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.